Free delivery over $100 Learn more

30 days return period Learn more
SKU: 0195ATC

OCI-AML2 Human Leukemia Specialized Cells

Tumor Cell Lines > Leukemia Cell Lines

Product Type: Human Leukemia Cell Lines

Species: Human

Cell Type: Other / Specialized Cells

Source Organ: Other

$1,249.00
Size

Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Cell Name: OCI-AML2

Tissue: peripheral blood; Tumor: leukemia, acute myeloid. Retinoic acid receptor gene expression.

  • Description
    OCI-AML2 is a human acute myeloid leukemia (AML) cell line derived from the peripheral blood of a 65-year-old male diagnosed with FAB M4 subtype in 1986. These cells exhibit typical round to oval morphology and grow in suspension without adherence. OCI-AML2 expresses hepatocyte growth factor (HGF), resulting in autocrine activation of the MET receptor tyrosine kinase, which supports cell survival, proliferation, and disease progression. The cell line is tumorigenic and capable of metastasis, making it highly suitable for studying AML signaling pathways, drug sensitivity, and disease relapse. Cells are pathogen-free (mycoplasma, bacteria, yeast, fungi), non-viral (HPV, HIV-negative), and are cryopreserved for consistent experimental use. It is widely used in both academic and pharmaceutical leukemia research.
  • Product Name
    OCI-AML2
  • Product Type
    Human Leukemia Cell Lines
  • Species
    Human
  • Disease
    Acute Myeloid Leukemia
  • Product Type
    Human Leukemia Cell Lines
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    OCI-AML2 cell line is broadly applied in leukemia research. It serves as a valuable tool for investigating AML cell biology and treatment response of acute myeloid leukemia (AML) cells. Researchers rely on OCI-AML2 to gain insights into the role of DNMT3A in leukemogenesis and to establish connections between drug response and DNMT3A mutational status across different AML genetic backgrounds. Furthermore, OCI-AML2 is employed in the designing targeted therapies against AML-driving receptors in AML by designing approaches that block compensatory ligand expression.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    α MEM + 10% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you